Policy Agenda

The membership of the Prostate Cancer Roundtable has come together around a continuing, shared, national policy agenda — in the interests of the hundreds of thousands of American men who are at risk each year for a diagnosis of prostate cancer and the estimated 2.2 million men living today who have been diagnosed with this highly prevalent form of cancer.

The fundamental priorities of the 2013 Prostate Cancer Roundtable National Policy Agenda are found below. Click here to print a copy of the Policy Agenda to distribute to your members and supporters, and to share with policy makers and elected officials.

Effective January 1, 2013 – Updated December 2013

  • We continue to seek an increase in the appropriation to support the successful work of the Prostate Cancer Research Program within the Department of Defense’s Congressionally Directed Medical Research Program – from its current $80 million to $120 million per year.
  • We continue to work with the broader cancer community to support increased federal funding for cancer research through the annual appropriations process for the National Institutes of Health, the National Cancer Institute, and the Centers for Disease Control.
  • Within the annual appropriation for the National Cancer Institute, we seek an increase in the current funding of $288 million for basic and translational prostate cancer research to $400 million per year.
  • We seek passage of a bill to create an Office on Men’s Health within the Department of Health and Human Services (HHS) that can mirror the 20-year successes of the Office on Women’s Health established in 1991.
  • We support legislative, research, and educational efforts needed to effectively combat – and ideally to eliminate — the epidemic of prostate cancer among African American men.
  • We seek the establishment of a Prostate Cancer Scientific Advisory Board for the Office of the Chief Scientist at the US Food & Drug Administration (FDA), with the goal of accelerating the real-time sharing of the latest research data and the movement of new medicines into clinical practice in the best interests of patients.
  • We seek revisions to the decision-making processes of the US Preventive Services Task Force (USPSTF) to ensure appropriate input from representatives of patient advocacy groups, specialty medical groups, and other federal agencies that have expertise in each area of preventive services under review.
  • We seek and encourage the inclusion of quality-of-life-related endpoints, based on patient-reported outcomes data, in pivotal trials of all biologic and pharmaceutical agents being assessed for regulatory approval in the treatment of prostate cancer with a primary endpoint of improved survival — such that quality-of-life-related data (positive or negative) as well as survival data can be included in labeling for products indicated for treatment of prostate cancer as and when appropriate.

If your organization wishes to support this joint, national policy agenda, please let us know so that we can add your organization’s name to the list of partners supporting this agenda.